Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

AACR 2023 | The role of NT219 in enhancing anti-PD-1 efficacy

Ricardo De Azevedo, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an assessment of NT219, a novel dual inhibitor of insulin receptor substrates 1 and 2 (IRS) and STAT3, in combination with anti-PD-1 and anti-CTLA-4 ICB, to overcome immune resistance. A significant synergistic effect of NT219 combined with anti-PD-1 therapy, supported by a mechanism of PDL-1 induction making immune checkpoint inhibitor (ICI) resistant tumors amenable to ICI treatment, was found. The findings demonstrated that NT219 has the potential to reverse ICI resistance in both human PDX and murine syngeneic tumor model systems. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.